• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nu Skin Enterprises Inc.

    6/1/26 5:20:09 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email
    S-8 1 ef20074947_s8.htm FORM S-8
    As filed with the Securities and Exchange Commission on June 1, 2026.
     
    Registration No. 333-______

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     

     
    NU SKIN ENTERPRISES, INC.
    (Exact name of registrant as specified in its charter)
     

     
       
    Delaware   87-0565309
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
    75 West Center Street
    Provo, Utah 84601
    (Address of Principal Executive Offices) (Zip Code)
     
    Nu Skin Enterprises, Inc. Amended and Restated 2024 Omnibus Incentive Plan
    (Full title of the plan)
     
    Chayce D. Clark
    Executive Vice President, Chief Operating Officer and Chief Legal Officer
    Nu Skin Enterprises, Inc.
    75 West Center Street
    Provo, Utah 84601
     (801) 345-1000
    (Name, address and telephone number, including area code, of agent for service)
     

    With copies to:
    Jay H. Knight
    Barnes & Thornburg LLP
    1600 West End Avenue, Suite 800
    Nashville, TN 37203-3494
    (615) 621-6100
     

     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
         
     
    Large accelerated filer
    ☐
    Accelerated filer
    ☑
     
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
        
    Emerging growth company
    ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
     

    1

    EXPLANATORY NOTE
     
    Nu Skin Enterprises, Inc., a Delaware corporation (the “Company”), previously filed a Registration Statement on Form S-8 (File No. 333-280044) registering 1,219,919 shares of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), under the Company’s 2024 Omnibus Incentive Plan, on June 7, 2024. The 2024 Omnibus Incentive Plan was initially approved by stockholders on June 5, 2024. On March 31, 2025, the Company’s Board of Directors approved the Amended and Restated 2024 Omnibus Incentive Plan to increase the number of shares authorized thereunder and to make certain other updates, subject to stockholder approval. The Amended and Restated 2024 Omnibus Incentive Plan was approved by the Company’s stockholders at the 2025 Annual Meeting of Stockholders. The Company previously filed a Registration Statement on Form S-8 (File No. 333-287723) registering an additional 790,000 shares of Common Stock under the Amended and Restated 2024 Omnibus Incentive Plan on June 2, 2025. Pursuant to General Instruction E to Form S-8, the contents of the previously filed Registration Statements, including any amendments thereto or filings incorporated therein, are incorporated herein by reference, except as modified, supplemented or superseded herein.
     
    On March 30, 2026, the Company’s Board of Directors approved and adopted a second amendment and restatement of the Amended and Restated 2024 Omnibus Incentive Plan (as collectively amended, the “Amended Plan”), primarily to increase the number of shares authorized under the Amended Plan by 2,850,000 shares, subject to stockholder approval at the 2026 Annual Meeting of Stockholders. The Amended Plan was later approved by the Company’s stockholders at the 2026 Annual Meeting of Stockholders.
     
    Pursuant to General Instruction E of Form S-8, this Registration Statement on Form S-8 is being filed by the Company to register an aggregate of 5,700,000 shares of the Company’s Common Stock consisting of (i) 2,850,000 shares of Common Stock representing the additional shares authorized under the Amended Plan, as approved by the stockholders at the 2026 Annual Meeting of Stockholders on May 28, 2026 and (ii) up to 2,850,000 shares of Common Stock subject to awards under the Amended Plan that have been or may in the future be forfeited, terminated, canceled, expired or settled in cash (in whole or in part) and therefore may become available for issuance pursuant to new awards in accordance with the terms and conditions of the Amended Plan (the “Forfeited Shares”). The actual number of Forfeited Shares that may become available for issuance under the Amended Plan may be less than 2,850,000 shares of Common Stock depending on, among other variables, the number of actual Amended Plan shares of Common Stock that become forfeited, terminated, canceled, expired or settled in cash. The Forfeited Shares do not represent an increase in the total number of shares of Common Stock that may be issued pursuant to the Amended Plan.
     
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    Item 3.
    Incorporation of Documents by Reference.
     
    The following documents, which have been filed with the Securities and Exchange Commission (the “Commission”) by the Company, are incorporated by reference in this Registration Statement, except to the extent that information therein is deemed furnished and not filed pursuant to securities laws and regulations:
     
    (a)
    the Company’s Annual Report on Form 10-K for the year ended December 31, 2025;
     
    (b)
    the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026;
     
    (c)
    the Company’s Current Reports on Form 8-K filed on March 9, 2026, March 20, 2026, March 27, 2026, May 8, 2026 and May 29, 2026; and
     
    (d)
    the description of the Company’s Class A Common Stock filed as Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on February 15, 2024, together with any amendment or report filed with the Commission for the purpose of updating such description.
     
    All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), subsequent to the date hereof and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents.
     
    2

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
     
    Item 8.
    Exhibits.
     
    Unless otherwise noted, the SEC file number for exhibits incorporated by reference is 001-12421.
     
      
    Exhibit
    Number
    Description of Document
    4.1
    Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 filed September 16, 1996, File No. 333-12073).
       
    4.2
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed March 1, 2010).
       
    4.3
    Certificate of Designation, Preferences and Relative Participating, Optional and Other Special Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof (incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, filed March 15, 2005).
       
    4.4
    Sixth Amended and Restated Bylaws of Nu Skin Enterprises, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed November 1, 2024).
       
    4.5
    Specimen Form of Stock Certificate for Class A Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 16, 2023).
       
    5.1*
    Opinion of Barnes & Thornburg LLP.
       
    23.1*
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
       
    23.2*
    Consent of Barnes & Thornburg LLP (included as part of Exhibit 5.1).
       
    24.1*
    Power of Attorney (included in the signature pages to this Registration Statement).
       
    99.1
    Nu Skin Enterprises, Inc. Amended and Restated 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 29, 2026).
       
    107.1*
    Filing Fee Table.
     

    *
    Filed herewith
     
    3

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Provo, State of Utah, on this 1st day of June, 2026.
     
         
     
    NU SKIN ENTERPRISES, INC.
     
       
     
    By:
    /s/ Ryan S. Napierski
     
    Name:
    Ryan S. Napierski
     
    Title:
    President and Chief Executive Officer
     
    POWER OF ATTORNEY
     
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan S. Napierski, Chayce D. Clark and Gregory S. Belliston, and each of them, any of whom may act without joinder of the other, the individual’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.
     
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the 1st day of June, 2026.
     
    4

         
      Signature   Title  
            
     
    /s/ Steven J. Lund
     
    Executive Chairman of the Board
     
     
    Steven J. Lund
     
            
     
    /s/ Ryan S. Napierski
     
    President, Chief Executive Officer and Director
    (Principal Executive Officer)
     
     
    Ryan S. Napierski
     
            
     
    /s/ Chelsea K. Lantz
     
    Chief Financial Officer
    (Principal Financial Officer and Accounting Officer)
     
     
    Chelsea K. Lantz
     
            
     
    /s/ Emma S. Battle
     
    Director
     
     
    Emma S. Battle
     
            
     
    /s/ Daniel W. Campbell
     
    Director
     
     
    Daniel W. Campbell
     
            
     
    /s/ Laura Nathanson
     
    Director
     
     
    Laura Nathanson
     
            
     
    /s/ Thomas R. Pisano
     
    Director
     
     
    Thomas R. Pisano
     
            
     
    /s/ James M. Winett
     
    Director
     
     
    James M. Winett
     
            
     
    /s/ Edwina D. Woodbury
     
    Director
     
     
    Edwina D. Woodbury
     
            
     
    /s/ Mark A. Zorko
     
    Director
     
     
    Mark A. Zorko
     
     
     

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winett James M was granted 26,643 shares and sold $40,481 worth of shares (7,203 units at $5.62) as part of a pre-agreed trading plan, increasing direct ownership by 108% to 37,448 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:10:22 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Nathanson Laura was granted 26,643 shares, increasing direct ownership by 87% to 57,116 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:09:32 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Zorko Mark A was granted 26,643 shares, increasing direct ownership by 78% to 60,586 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:08:41 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form S-8 filed by Nu Skin Enterprises Inc.

    S-8 - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    6/1/26 5:20:09 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    5/29/26 4:05:27 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form SD filed by Nu Skin Enterprises Inc.

    SD - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    5/21/26 6:02:40 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nu Skin Enterprises Reports First Quarter Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environ

    5/7/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 10, 2026, to shareholders of record on May 29, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal car

    5/7/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce First Quarter 2026 Financial Results

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2026 results after the market closes on Thursday, May 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 21. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family

    4/13/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises Reports First Quarter Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environ

    5/7/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 10, 2026, to shareholders of record on May 29, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal car

    5/7/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce First Quarter 2026 Financial Results

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2026 results after the market closes on Thursday, May 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 21. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family

    4/13/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care